July 7, 2022

 

Via EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attn:     Ada D. Sarmento

 

 

Re:	Calliditas Therapeutics AB
	Registration Statement on Form F-3
	Filed June 28, 2022
	File No. 333-265881

 

	Acceleration Request
		Requested Date: July 8, 2022
		Requested Time: 4:00 p.m. Eastern Time

 

Ladies and Gentlemen:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-3 (File No. 333-265881) (the “Registration Statement”), to become effective on July 8, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the Commission’s staff. The Registrant hereby authorizes Joshua Kaufman of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Joshua Kaufman of Cooley LLP at (212) 479-6495.

 

[Signature page follows]

 

 

	Very truly yours,
	Calliditas Therapeutics AB
	By:	/s/ Renée Aguiar-Lucander
	Renée Aguiar-Lucander
	Chief Executive Officer

 

cc:
	Fredrik Johansson, Calliditas Therapeutics AB
	Jonathan Schur, Calliditas Therapeutics AB
	Josh Kaufman, Cooley LLP
	Katie Kazem, Cooley LLP
	Dain Hard Nevonen, Advokatfirman Vinge KB
	Linnea Sellström, Advokatfirman Vinge KB